Overactive bladder: Is there a link to the metabolic syndrome in men?

Neurourology and Urodynamics

Volumn 29, Issue 8, 2010, Pages 1360-1364

  Kirby, Michael G ^a   Wagg, Adrian ^b   Cardozo, Linda ^c   Chapple, Christopher ^d   Castro Diaz, David ^e   De Ridder, Dirk ^f   Espuna Pons, Montserrat ^g   Haab, Francois ^h   Kelleher, Con ⁱ   Kólbl, Heinz ^j   Milsom, Ian ^k   Van Kerrebroeck, Philip ^l   Vierhout, Mark ^m   Salvatore, Stefano ⁿ   Tubaro, Andrea ^o  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^e HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF BARCELONA   (Spain)

^h HÔPITAL TENON   (France)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF INSUBRIA   (Italy)

^o SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

benign prostatic hyperplasia; erectile dysfunction; LUTS; metabolic syndrome; overactive bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATORVASTATIN; FINASTERIDE; MEPARTRICIN; MEVINOLIN; PLACEBO; SIMVASTATIN;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERINSULINEMIA; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NONHUMAN; OVERACTIVE BLADDER; PROSTATE HYPERTROPHY;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; ERECTILE DYSFUNCTION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERINSULINISM; MALE; METABOLIC SYNDROME X; PROSTATIC HYPERPLASIA; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 78349274526     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20892     Document Type: Article

References (42)

1. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: A broader clinical perspective. Eur Urol 2008; 54: 563-9.
2. Chapple CR, Roehrborn CG,. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006; 49: 651-9.
3. Feldman H, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlate: Results of the Massachusetts Male Aging Study. J Urol 1994; 150: 54-61.
4. Men's Health. In:, Kirby RS, Kirby MG, Farah RN, editors. Isis. Medical Media Ltd. 1999. Chapter 12a, pp. 125-36.
5. Eckel RH, Grundy SM, Zimmet PZ,. The metabolic syndrome. Lancet 2005; 365: 1415-28.
6. Alberti KG, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and it's complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
7. Scott M, Grundy H, Brewer B, et al. Definition of metabolic syndrome: Report of the National Heart Lung and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
8. International Diabetes Federation. 2006. The IDF consensus worldwide definition of the metabolic syndrome. Available at: (accessed 02/10/09).
9. Oda E,. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008; 31: 1283-91.
10. Yudkin JS,. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med 1996; 28: 433-8.
11. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
12. Ford ES, Giles WH, Dietz WH,. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
13. Straznicky NE, Eikelis N, Lambert EA, et al. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 2008; 10: 440-7.
14. Kasturi S, Russell S, McVary KT,. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7: 288-92.
15. Wein AJ,. Overactive bladder: Defining the disease. Am J Manag Care 2000; 6: S559-64.
16. McVary KT, Razzaq A, Lee C, et al. Growth of the rate prostate glad is facilitated the autonomic nervous system. Biol Reprod 1994; 51: 99-107.
17. Golomb E, Rosenzweig N, Eilam R, et al. Spontaneous hyperplasia of the ventral lobe of the rate in aging genetically hypertensive rates. J Androl 2000; 21: 58-64.
18. Steers WD, Clemow DB, Persson K, et al. The spontaneously hypertensive rat: Insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999; 84: 137-47.
19. Tong YC, Cheng JT,. Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007; 178: 1537-42.
20. Lee WC, Chien CT, Yu HJ, et al. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol 2008; 179: 2470-6.
21. Hammarsten J, Hogstedt B,. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
22. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-944.
23. McVary KT, Rademaker A, Lloyd GL, et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327-433.
24. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
25. Roehrborn CG, McConnell JD, Kusek J, et al. Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flow rate in MTOPS [Abstract 910]. J Urol 2004; 171: 241.
26. Rohrmann S, Smit E, Giovannucci E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005; 29: 310-16.
27. Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203.
28. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26: 40-9.
29. Dal Maso L, Zucchetto A, Tavani A, et al. Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 2006; 118: 2632-5.
30. Hammarsten J, Hogstedt B,. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-95.
31. Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009; 12: 160-5.
32. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637-49.
33. Kaplan SA,. Metabolic dysfunction and male pelvic health. Eur Urol 2007; 52: 316-17.
34. Esposito K, Giugliano F, Martedi E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201-3.
35. Paick JS, Yang JH, Kim SW, et al. Are age, anthropometry and components of metabolic syndrome-risk factors interrelated with lower urinary tract symptoms in patients with erectile dysfunction? A prospective study. Asian J Androl 2007; 9: 213-20.
36. Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009; 12: 29-34.
37. Irwin DE, Milsom I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 2008; 5: 2904-10.
38. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-304.
39. Marino G, Pugno E, Cevoli R, et al. Pharmacologic treatment of benign prostatic hypertrophy (BPH): A combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 1991; 43: 279-82.
40. Mills IW, Crossland A, Patel A, et al. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 2007; 52: 503-9.
41. Stamatiou KN, Zaglavira P, Skolarikos A, et al. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 2008; 34: 555-62.
42. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.